The massive GAAP EPS miss (-$0.68 vs -$0.22 consensus) driven by $168M other operating expense and a $93M tax provision will likely pressure the stock near-term despite the revenue beat and strong guidance. Watch the earnings call for clarity on the other operating expense line and whether the FY2027 adjusted EBITDA margin guidance of ~16% implies meaningful GAAP improvement. The MiniMed Flex launch this month and Abbott partnership extension are positive catalysts but may take time to flow through to GAAP profitability.
Price Chart
Executive Summary
MiniMed reported Q4 FY2026 net sales of $837M (+15.6% YoY as reported, +8.7% organic), surpassing $3B in annual revenue for the first time. The company guided FY2027 organic revenue growth of ~10% and adjusted EBITDA margin of ~16%. However, GAAP net loss widened to -$183M in Q4 (from -$168M a year ago) and EPS was -$0.68, significantly below the -$0.22 consensus estimate, driven by $168M in other operating expense and a $93M income tax provision. The combination of strong top-line growth and expanding product pipeline with deteriorating GAAP profitability and a massive EPS miss creates a mixed picture.
Key Financial Metrics
Key Facts
- Q4 FY2026 net sales $837M, +15.6% as reported YoY, +8.7% organic
- Full-year FY2026 net sales $3.102B, +14.2% as reported, +8.0% organic (first time above $3B)
- GAAP net loss attributable to company Q4: -$183M vs -$172M YoY; FY: -$331M vs -$213M YoY
- GAAP diluted EPS Q4: -$0.68 (vs consensus -$0.22); FY: -$1.29 vs -$0.84
- FY2027 guidance: organic revenue growth ~10% (incl. 1.0-1.5% extra-week benefit), adjusted EBITDA margin ~16%
- CGM revenue grew 21.6% in Q4 to $420M; pumps declined 5.5% to $146M due to MiniMed Flex launch timing
- International net sales grew 22.4% as reported in Q4; U.S. grew only 1.5% as customers waited for Flex launch
- Abbott partnership extended to develop dual glucose-ketone sensors for MiniMed systems
Financial Impact
Q4 GAAP EPS -$0.68 vs consensus -$0.22 (miss of -209%); Q4 revenue $837M vs consensus $826.5M (beat of +1.3%)
Risk Factors
- GAAP profitability continues to deteriorate with operating loss widening to -$91M in Q4 from -$148M a year ago
- U.S. revenue growth stalled at 1.5% as customers delayed purchases for MiniMed Flex — execution risk on new product ramp
- Other operating expense surged to $168M in Q4 from $4M a year ago — unclear if this is recurring
- Income tax provision of $93M on a pre-tax loss of -$90M is unusual and may raise questions about deferred tax valuation allowances
- Pump sales declined 5.5% YoY in Q4 — core hardware business under pressure from CGM shift
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040036 |
| Document: mmed-20260603.htm | 0001628280-26-040036 |
| Document: 0001628280-26-040036-index-headers.html | 0001628280-26-040036 |
| Document: 0001628280-26-040036-index.html | 0001628280-26-040036 |
| Document: 0001628280-26-040036.txt | 0001628280-26-040036 |
| 8-K Data (Synthetic) | 0001628280-26-040036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 14, 2026 18d ago | S-4 / 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.70 (−10.33%) |
Sep 1, 2026 4w ago | 8-K | $22.42 $22.76 | ▲ +1.52% | ▲ +1.44% | $19.70 (−12.13%) |
Jul 6, 2026 12w ago | 3 | $15.37 $15.04 | ▼ −2.15% | ▼ −2.70% | $19.70 (+28.17%) |
Jun 29, 2026 13w ago | 8-K | $14.88 $15.29 | ▲ +2.76% | ▲ +1.37% | $19.70 (+32.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access